ANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP - Free Report) in a research note issued to investors on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $80.00 target price on the specialty pharmaceutical company's stock.

Other analysts have also issued reports about the company. Leerink Partnrs upgraded ANI Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, December 11th. StockNews.com lowered ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, March 3rd. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. Finally, Guggenheim boosted their price target on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, ANI Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $79.75.

Remove Ads

ANI Pharmaceuticals Trading Down 0.2 %

ANIP stock traded down $0.13 during midday trading on Friday, hitting $64.22. 233,027 shares of the company's stock were exchanged, compared to its average volume of 238,092. The stock's fifty day moving average price is $58.59 and its 200-day moving average price is $58.07. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The company has a market cap of $1.40 billion, a PE ratio of -116.76 and a beta of 0.63. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.81.

Insider Activity at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now owns 66,525 shares of the company's stock, valued at approximately $4,048,711.50. The trade was a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,200 shares of company stock valued at $191,776. 12.70% of the stock is owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. US Bancorp DE increased its position in ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares during the last quarter. KBC Group NV increased its position in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after buying an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in ANI Pharmaceuticals during the fourth quarter worth approximately $166,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock worth $177,000 after buying an additional 579 shares during the last quarter. Finally, Rafferty Asset Management LLC acquired a new position in ANI Pharmaceuticals during the fourth quarter worth approximately $200,000. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.